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Occult hepatitis B virus infection: diagnosis, implications and 
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Abstract Occult hepatitis B virus (HBV) infection is generally defined as the detection of HBV-DNA
in the serum or liver tissue of patients who test negative for hepatitis B surface antigen. In most cases,
occult HBV infection is related to low level HBV infection with subdetectable levels of HBsAg and not
infection with HBV variants that cannot express S proteins or produce S proteins with aberrant epitopes
that are not detected by conventional serological assays. Prevalence of occult HBV infection is related to
the overall prevalence of HBV infection in that country, being more common in persons with prior expo-
sure to HBV. Occult HBV infection has been found in a substantial proportion of patients with cirrhosis
and hepatocellular carcinoma but other causes of liver disease are frequently present. Future studies
should focus on delineating the pathogenic role of occult HBV infection and the basis for failure to detect
circulating hepatitis B surface antigen.
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Occult hepatitis B virus (HBV) infection is generally
defined as the detection of HBV-DNA in the serum or
liver tissue of patients who test negative for hepatitis B
surface antigen (HBsAg).1 Key questions regarding
occult HBV infection include: How should occult HBV
infection be diagnosed? What is the prevalence of occult
HBV infection? Does occult HBV infection lead to
development of cirrhosis and hepatocellular carcinoma
(HCC)? What is the basis for the failure to detect cir-
culating HBsAg? Can occult HBV infection be trans-
mitted? How should patients with occult HBV infection
be managed?
HOW SHOULD OCCULT HBV 
INFECTION BE DIAGNOSED?
An important observation in patients with occult HBV
infection is the low HBV DNA levels: 102-3 copies/mL
in the serum and 0.01–0.1 copy per liver cell.2,3 The fre-
quency of detection of HBV DNA is higher in liver tis-
sue than in serum, and more often in frozen than in
paraffin-embedded liver tissue. Thus, the material used
for HBV DNA detection and the sensitivity of the assay
can influence the result. Because of the low amounts of
HBV DNA, ultra-sensitive polymerase chain reaction
(PCR) assays, with detection limits of less than
10 copies of HBV DNA per reaction are increasingly
used.4 It is therefore important to confirm the specificity
of the assays and to ensure that all necessary precau-
tions to prevent cross-contamination have been taken. It
has been proposed that diagnosis of occult HBV infec-
tion be made only when HBV DNA can be detected
using at least two sets of primers from different areas of
the HBV genome in duplicate assays.1,4 Appropriate
negative controls must be included in each assay and
specificity of the amplification reaction confirmed by
sequencing of the amplicons. Precautions to prevent
cross-contamination should be used not only during
DNA extraction and PCR amplification but also during
sample collection and processing.
WHAT IS THE PREVALENCE OF 
OCCULT HBV INFECTION?
Prevalence of occult HBV infection is related to the
overall prevalence of HBV infection in that country.
Occult HBV infection has been reported in 7–19% of
blood donors in endemic areas where 70–90% of the
population had been exposed to HBV, and in 0–9% in
Western countries such as the United States where only
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5% of the population had prior exposure to HBV.5–8
Prevalence of occult HBV infection is also related to the
presence of markers of HBV exposure. Thus, prevalence
of occult HBV infection is higher in seropositive persons
particularly those who are positive for hepatitis B core
antibody (anti-HBc) only, than seronegative persons
who are negative for anti-HBc as well as hepatitis B sur-
face antibody (anti-HBs). Several studies reported a
high prevalence of occult HBV infection among hepa-
titis C patients.9,10 This is likely related to common risk
factors. Prevalence of occult HBV infection is also
related to the population studied; rates of detection of
serum HBV DNA increasing from 5–50% among
patients with chronic hepatitis to 20–60% among
patients with cirrhosis and HCC.4,11–13 The rates of
detection of HBV DNA in liver tissue are higher, up to
60–70% among patients with chronic hepatitis or
HCC.4,14,15
DOES OCCULT HBV INFECTION 
LEAD TO CIRRHOSIS AND 
HEPATOCELLULAR CARCINOMA 
(HCC)?
The pathogenic role of occult HBV infection is unclear.
Because occult HBV infection is more commonly found
in patients with cirrhosis or HCC than in those with
minimal liver injury, it has been thought that occult
HBV infection may result in cirrhosis and HCC. Sev-
eral studies found that patients coinfected with HBV
and HCV have increased risks of HCC compared to
those with mono-infection.16,17 The two viruses may
interact by causing more severe inflammation and accel-
erated progression to cirrhosis. Alternatively, direct
oncogenic effects of these two viruses may be additive or
synergistic. Similarly, occult HBV infection can be a
cofactor in the development of HCC among patients
with alcoholic liver disease or cirrhosis due to other eti-
ologies. Whether occult HBV infection alone causes cir-
rhosis and HCC is unclear. In studies from western
countries,15–17 most patients had other causes of liver
disease, notably hepatitis C or chronic alcohol use that
may on their own lead to cirrhosis and HCC, but con-
comitant causes of liver disease are frequently absent in
patients from Asian countries. Many of the latter
patients may have developed cirrhosis or HCC after
decades of chronic HBV infection but had spontane-
ously cleared HBsAg at the time of presentation (see
below).
WHAT IS THE BASIS FOR THE 
FAILURE TO DETECT 
CIRCULATING HBSAG?
Most studies find that occult HBV infection is related to
low level HBV infection with subdetectable levels of
HBsAg and not infection with HBV variants that cannot
express S proteins or variants that express S proteins
with aberrant epitopes that cannot be detected by con-
ventional serology assays.4 While some HBV S variants
such as the glycine-arginine substitution at codon 145
(G145R) may be missed by monoclonal antibody based
HBsAg assays, most HBV S variants can be detected by
polyclonal antibody based serology assays.18 Thus,
many patients with occult HBV infection could have
had overt chronic HBV infection for many years with
subsequent spontaneous clearance of HBsAg.19,20 Spon-
taneous clearance of HBsAg in patients with chronic
HBV infection has been reported to occur at the rate of
0.5–1% per year.21 Although the outcome of these
patients is improved, HCC has been reported.22 Other
patients might have transient acute HBV infection in
the past with serological recovery. Numerous studies
showed that low level HBV DNA can be detected in the
liver of these patients more than 10 years later.23 A
recent study from Japan found that inflammation and
fibrosis can be detected up to 10 years after serological
recovery from acute hepatitis B.24 These data, if con-
firmed, suggest that transient acute HBV infection can
result in chronic liver injury, underscoring the impor-
tance of HBV vaccination. In a landmark study by Bea-
sley et al. the incidence of HCC per 100 000 per year
was 495 and 5 among HBsAg carriers and anti-HBc
and/or anti-HBs positive subjects, respectively, com-
pared to 0 among seronegative persons.25 The finding of
a higher prevalence of occult HBV infection among
seropositive persons support the notion that occult
HBV infection is frequently a late phase of overt chronic
HBV infection or serologically recovered acute HBV
infection. The explanation for occult HBV infection in
seronegative patients is less clear. It is possible that
some of these patients had transient acute HBV infec-
tion with clearance of HBsAg initially and decline of
anti-HBc and anti-HBs titers to undetectable levels over
time. It is also possible that some patients are infected
with HBV variants that do not express any HBV pro-
teins. Further studies are needed to determine how fre-
quently this occurs and to characterize these variants.
CAN OCCULT HBV INFECTION BE 
TRANSMITTED?
Transmission of HBV infection has been documented
from HBsAg negative, anti-HBc positive blood and
organ donors. The risk is variable (0.4%-90%),7,26–28
and is highest when livers from anti-HBc positive
donors are transplanted to seronegative recipients. The
risk of transmission of HBV infection from seronegative
individuals has not been well studied. Although there
have been case reports of such transmission, the overall
risk is likely to be negligible.
HOW SHOULD PATIENTS WITH 
OCCULT HBV INFECTION BE 
MANAGED?
There are no data on the use of antiviral therapy in
patients with occult HBV infection. The likelihood of
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benefit is low as most patients with occult HBV infec-
tion have very low levels of HBV DNA. In the rare
patient with persistently high serum HBV DNA levels
and absence of other causes of liver disease, antiviral
therapy may be considered.
In summary, occult HBV infection is present in a
substantial proportion of patients with cirrhosis and
HCC; the exact prevalence varies in different parts of
the world and with the technique used for detection of
HBV DNA. Future studies should delineate the patho-
genic role of occult HBV infection and the basis for the
failure to detect circulating HBsAg. Until these critical
issues have been addressed, it is premature to advocate
testing all HBsAg negative patients with liver disease for
occult HBV infection and to recommend treatment
with antiviral agents.
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